Eli Lilly | LLY - Capital Ordinário





Capital Ordinário Alterar Data
AbbVie USD 1.77B 608K 2026-06
Abbott USD 1.74B 2.94M 2026-03
ALKERMES USD 168.03M 489K 2026-09
Amgen USD 541M 0 2026-09
AstraZeneca USD 1.55B 28K 2026-09
Baxter International USD 517M 549K 2026-06
Biogen USD 146.7M 200K 2025-09
Bristol-Myers Squibb USD 2.04B 7M 2026-06
Coherus Biosciences USD 121.16M 4.92M 2025-12
Drreddys Laboratories INR 833.07M 382K 2026-09
Eli Lilly USD 943.5M 3.33M 2026-03
Gilead Sciences USD 1.24B 1000K 2026-06
GlaxoSmithKline GBP 2.02B 2.05B 2026-09
Glaxosmithkline GBP 2.02B 2.03B 2026-09
J&J USD 2.41B 1.64M 2026-06
Medtronic USD 1.28B 130K 2026-06
Merck USD 2.47B 1.05M 2026-06
Neurocrine Biosciences USD 101.3M 750K 2026-09
Novartis USD 1.89B 12.09M 2026-09
Novartis USD 1.89B 19.47M 2026-09
Novo Nordisk DKK 4.43B 13.25M 2026-06
Perrigo USD 138.8M 700K 2026-09
Pfizer USD 5.7B 0 2026-06
Phibro Animal Health USD 40.48M 0 2025-12
Prestige Brands USD 47.37M 53K 2026-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Roche Holding CHF 796.77M 1.15M 2026-06
Sanofi EUR 1.2B 0 2026-09
Sanofi EUR 1.2B 2.15M 2026-06
United Therapeutics USD 42.38M 295K 2026-09
Zoetis USD 407.49M 6.67M 2026-09